Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study

The Lancet Haematology

Volumn 3, Issue 1, 2016, Pages e12-e21

  Ageno, Walter ^a   Mantovani, Lorenzo G ^b   Haas, Sylvia ^c   Kreutz, Reinhold ^d   Monje, Danja ^e   Schneider, Jonas ^f   van Eickels, Martin ^f   Gebel, Martin ^f   Zell, Elizabeth ^g   Turpie, Alexander G G ^h  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c Vascular Centre   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e BAYER AG   (Germany)

^f BAYER PHARMA AG   (Germany)

^g Stat Epi Associates Inc   (United States)

^h HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; FONDAPARINUX; HEPARIN; RIVAROXABAN; ANTICOAGULANT AGENT; POLYSACCHARIDE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; BUDD CHIARI SYNDROME; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEART INFARCTION; HUMAN; LENGTH OF STAY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORTALITY; MULTICENTER STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; UNSTABLE ANGINA PECTORIS; CHEMICALLY INDUCED; COMPARATIVE STUDY; MIDDLE AGED; PULMONARY EMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

AGED; ANTICOAGULANTS; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; POLYSACCHARIDES; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RIVAROXABAN; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84949683187     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00257-4     Document Type: Article

References (25)

1. Goldhaber, SZ, Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol 25 (2012), 235–242.
2. Silverstein, MD, Heit, JA, Mohr, DN, Petterson, TM, WM O'Fallon, Melton, LJ 3rd, Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158 (1998), 585–593.
3. Cushman, M, Tsai, AW, White, RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 117 (2004), 19–25.
4. Kearon, C, Akl, EA, Comerota, AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141 (2012), e419S–e494S.
5. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363 (2010), 2499–2510.
6. The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366 (2012), 1287–1297.
7. Agnelli, G, Buller, HR, Cohen, A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368 (2013), 699–708.
8. Agnelli, G, Buller, HR, Cohen, A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369 (2013), 799–808.
9. Schulman, S, Kearon, C, Kakkar, AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361 (2009), 2342–2352.
10. Schulman, S, Kearon, C, Kakkar, AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368 (2013), 709–718.
11. Schulman, S, Kakkar, AK, Goldhaber, SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129 (2014), 764–772.
12. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369 (2013), 1406–1415.
13. Ageno, W, Mantovani, LG, Haas, S, et al. XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. Thromb J, 12, 2014, 16.
14. Cano, SJ, Lamping, DL, Bamber, L, Smith, S, The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients. Health Qual Life Outcomes, 10, 2012, 120.
15. Dahabreh, IJ, Sheldrick, RC, Paulus, JK, et al. Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. Eur Heart J 33 (2012), 1893–1901.
16. Collins, GS, Le Manach, Y, Comparing treatment effects between propensity scores and randomized controlled trials: improving conduct and reporting. Eur Heart J 33 (2012), 1867–1869.
17. Fine, JP, Gray, RJ, A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999), 496–509.
18. Rosendaal, FR, Cannegieter, SC, van der Meer, FJ, Briet, E, A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69 (1993), 236–239.
19. Williamson, E, Morley, R, Lucas, A, Carpenter, J, Propensity scores: from naive enthusiasm to intuitive understanding. Stat Methods Med Res 21 (2012), 273–293.
20. Beyer-Westendorf, J, Förster, K, Pannach, S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC Registry. Blood 124 (2014), 955–962.
21. Nieto, JA, Camara, T, Gonzalez-Higueras, E, et al. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100 (2008), 789–796.
22. Spyropoulos, A, Lin, J, Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 13 (2007), 475–486.
23. Dasta, JF, Pilon, D, Mody, SH, et al. Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy. J Med Econ, 2015, 10.3111/13696998.2015.1074583 published online Aug 26.
24. van Bellen, B, Bamber, L, Correa de Carvalho, F, Prins, M, Wang, M, Lensing, AWA, Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 30 (2014), 829–837.
25. Merli, GJ, Hollander, JE, Lefebvre, P, et al. Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban. Hosp Pract (1995) 43 (2015), 85–93.